List of Excipients in API saxagliptin and metformin hydrochloride
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing saxagliptin and metformin hydrochloride
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | KOMBIGLYZE | saxagliptin and metformin hydrochloride | 0310-6125 | CARBOXYMETHYLCELLULOSE SODIUM | |
| AstraZeneca Pharmaceuticals LP | KOMBIGLYZE | saxagliptin and metformin hydrochloride | 0310-6125 | HYPROMELLOSE 2208 | |
| AstraZeneca Pharmaceuticals LP | KOMBIGLYZE | saxagliptin and metformin hydrochloride | 0310-6125 | MAGNESIUM STEARATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing saxagliptin and metformin hydrochloride
Detailed excipient profiles for saxagliptin and metformin hydrochloride
Excipient focus: CARBOXYMETHYLCELLULOSE SODIUM
saxagliptin and metformin hydrochloride drug variants containing CARBOXYMETHYLCELLULOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing CARBOXYMETHYLCELLULOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
saxagliptin and metformin hydrochloride drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
saxagliptin and metformin hydrochloride drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
saxagliptin and metformin hydrochloride drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
saxagliptin and metformin hydrochloride drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
saxagliptin and metformin hydrochloride drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2208
saxagliptin and metformin hydrochloride drug variants containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
saxagliptin and metformin hydrochloride drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
saxagliptin and metformin hydrochloride drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
saxagliptin and metformin hydrochloride drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
saxagliptin and metformin hydrochloride drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
saxagliptin and metformin hydrochloride drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 8000
saxagliptin and metformin hydrochloride drug variants containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
saxagliptin and metformin hydrochloride drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K90
saxagliptin and metformin hydrochloride drug variants containing POVIDONE K90
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing POVIDONE K90
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
saxagliptin and metformin hydrochloride drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
saxagliptin and metformin hydrochloride drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
saxagliptin and metformin hydrochloride drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
saxagliptin and metformin hydrochloride drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
saxagliptin and metformin hydrochloride drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| DrReddys Laboratories Inc | saxagliptin and metformin hydrochloride | 43598-620 |
| >Company | >Ingredient | >NDC |
saxagliptin and metformin hydrochloride drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | saxagliptin and metformin hydrochloride | 0310-6125 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links